Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Viscera Labs Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being examined within 1 distinct art unit, reflecting a very specific technical focus for the company's current IP activity. With only 1 pending office action, the prosecution effort is entirely concentrated on a single application. Practitioners should note that the concentration in a single art unit allows for a deep focus on specific biotechnology standards.
The case is assigned to 1 distinct examiner, LEE, SIN J, who is also the busiest examiner with 1 pending office action. Because LEE, SIN J is the only examiner involved, the success of the current prosecution depends entirely on the interaction with this specific individual. Practitioners should focus on the examination history of this examiner to advance the 1 pending office action toward allowance without unnecessary delays.
The data shows a simple prosecution profile with 1 distinct examiner and 1 distinct art unit. This lack of complexity allows for a very targeted strategy. The busiest examiner, LEE, SIN J, manages the entirety of the active portfolio, making their feedback the most critical factor for the 1 pending office action in the Biotechnology & Pharmaceuticals area within the patent office's framework.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, SIN J | 1 | 68.8% | +25.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19014498 | Therapeutic Composition and Methods | LEE, SIN J | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19014498 | Therapeutic Composition and Methods | LEE, SIN J | 1613 | §112 | Non-Final OA | — | Pending | Jan 09, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialViscera Labs Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sin J Lee has the most, with 1 of Viscera Labs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
